What are the consequences of skipping early-stage process development in recombinant protein production?
The temptation is clear: move fast, reach large-scale/GMP production, and save time upfront. However, bypassing a pre-scale development phase can jeopardize the entire program, as hidden risks often surface later, when they are most costly and time-consuming to resolve.
Risks of Skipping Early-Stage (pre-GMP) Process Development
- Delays & Cost Escalation: Additional tech-transfer effort and optimization cultivations at the CDMO extend timelines and drive up development costs.
- Product Variability: Inconsistencies in fermentation output hinder DSP development and prevent definition of critical quality attributes (CQAs).
- Regulatory Setbacks: Modifications to key process parameters or expression strains at later development stages necessitate comprehensive re-validation and regulatory re-submission, causing significant delays in clinical and commercial progression.
- Batch Failures: Unmet release criteria can lead to GMP batch rejection and repeated production runs, increasing costs and delays.
- Program Risks: Accumulated setbacks erode stakeholder confidence, create funding gaps, and threaten program continuity.
Each of these outcomes can derail even the most promising biopharmaceutical program, underscoring the value of thorough, early-stage process development to ensure robust, scalable, and regulatory-compliant production.
A smarter path: build robustness early
Building robust and reproducible processes before scale-up can significantly reduce late-stage risks and promote long-term manufacturing success.
At VALIDOGEN, we help our partners de-risk their development programs through:
- Comprehensive Pichia pastoris strain and fermentation process development, tailored to product-specific needs
- Protein production process optimization for maximizing performance, productivity, and process robustness
- Validation-like confirmation runs to build confidence for robust performance at scale
- Transfer-ready documentation and support to ensure a smooth and efficient CDMO handover
The investment in early process development is minimal compared to the cost of late-stage rework, repeated GMP campaigns, or missed clinical milestones. Early robustness is not a delay - it’s an accelerator toward successful, sustainable biomanufacturing.
Contact us to learn more about VALIDOGEN’s early process development programs.
